表皮生長(zhǎng)因子受體(EGFR)活性蛋白
Active Epidermal Growth Factor Receptor (EGFR)
ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
- 編號(hào)APA757Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點(diǎn)6.7
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 840 ¥ 2100 ¥ 4200 ¥ 12600 ¥ 31500
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. In addition, the interaction of Heparin Binding Epidermal Growth Factor Like Growth Factor (HBEGF) and EGFR can activate the EGFR signaling pathway, and then affect the biological behaviors of cell proliferation, differentiation and migration. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human EGFR and recombinant human HBEGF. Briefly, EGFR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to HBEGF-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-EGFR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human EGFR and recombinant human HBEGF was shown in Figure 1, the EC50?for this effect is 0.16 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
APA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
APA757Hu62 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA757Hu61 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA757Hu62 | 表皮生長(zhǎng)因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA757Hu61 | 表皮生長(zhǎng)因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA757Hu06 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
PAA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
PAA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
FAA757Hu51 | 抗表皮生長(zhǎng)因子受體(EGFR)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) | FCM |
MAA757Hu27 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu29 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
RAA757Hu21 | 表皮生長(zhǎng)因子受體(EGFR)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
MAA757Hu21 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu23 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu24 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu25 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu22 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC |
SEA757Hu | 表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
HEA757Hu | 表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
AEA757Hu | 抗表皮生長(zhǎng)因子受體抗體(Anti-EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
LMA757Hu | 表皮生長(zhǎng)因子受體(EGFR)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Thoracic Cancer | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer [Wiley: source] |
J Cent Nerv Syst Dis.? | Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … [Pubmed:25249767] |
Mol Cancer Ther | GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands [PubMed: 26586721] |
Cell Death Dis.? | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway [Pubmed:26938303] |
analytica chimica acta | Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. [pubmed:28335979] |
Talanta | EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform [Doi: 10.1016/j.talanta.2018.10.016] |
Bioorganic Chemistry | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers [Pubmed: 30665034] |
Journal of?enzyme?inhibition and medicinal chemistry | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile [Pubmed: 30919701] |
Bioorganic Chemistry | Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents [] |
Bioorganic Chemistry | Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study [Pubmed: 31288134] |
Oxidative Medicine and Cellular Longevity | Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?… [Pubmed: 31737175] |
Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung [] | |
Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives [] | |
IMMUNOLOGIC RESEARCH | Humoral immune response to epidermal growth factor receptor in lung cancer [33495907] |
European Journal of Medicinal Chemistry | Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents [33545637] |
Journal of Molecular Structure | Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors [] |
ACS Appl Mater Interfaces | Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions [34914377] |
Bioorganic Chemistry | Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies [Pubmed:35219045] |